Sat.Sep 19, 2020 - Fri.Sep 25, 2020

article thumbnail

Innovate UK funding for new precision cancer treatment technology

pharmaphorum

Sixfold Bioscience and Medicines Discovery Catapult awarded Innovate UK grant to pursue ground-breaking project. Sixfold Bioscience in partnership with Medicines Discovery Catapult, has been given the green light, through the award of an Innovate UK Smart Grant to test a pioneering system designed to deliver drugs directly to cancerous cells, without impacting the healthy cells around it.

141
141
article thumbnail

The Themes of The World Pharmacists Day 2010-2020

Pharma Mirror

Pharmacists are healthcare professionals who have enough knowledge about the effective uses of medications. World Pharmacist Day is celebrated on 25th September every year since 2010 on the day FIP (International Pharmaceutical Federation) started their journey. FIP encourages pharmacists to celebrate this day to promote and support the role of the pharmacist in the whole.

97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Baby Thrush Treatment Over The Counter

Druggist

Baby thrush (oral thrush) is a common condition caused by candida infection (fungal infection) and mostly affecting new-born babies. Thrush can affect breastfeeding mothers (thrush present in the breast) and babies, with thrush affecting the inside of the mouth or causing a nappy rash. This post will focus on the treatment of oral baby thrush. Parents have only one option for baby thrush treatment – over the counter antifungal oral gel (Daktarin Sugar-Free 2% Oral Gel), which be purchased

article thumbnail

Eschbach: better communication boosts pharma manufacturing

Outsourcing Pharma

A leader from the pharma software solutions provider suggests streamlining communication between shifts can avoid manufacturing snags.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Vertical pharma: How sector convergence can erase digital health siloes

pharmaphorum

Life science companies must evolve and find new ways of working that erase the lines between industries and sub-sectors if they are to adapt to the digitalised world. That’s according to the team at Sweden’s Sahlgrenska Science Park, who are getting ready to host a virtual event looking at how the specialisation of digital expertise is driving a trend of sector convergence that pharma is only just cottoning on to.

article thumbnail

Governments have a public health duty to expand vaccination coverage through pharmacies, FIP says

Pharma Mirror

The Hague — Governments and other stakeholders must take urgent action to ensure equity in access to disease prevention measures, which includes greater investment in vaccines and vaccination services by community pharmacists. So said the International Pharmaceutical Federation (FIP) in a call to action made today at the start of a new FIP Digital Programme to.

More Trending

article thumbnail

Deloitte survey reveals pharma CEO thoughts

Outsourcing Pharma

The latest iteration of the companyâs Pharma CEO Survey offers information and insight as to how key industry figures are planning for the future.

57
article thumbnail

Could a COVID-19 breath test help UK out of lockdown?

pharmaphorum

A potential COVID-19 breath test has been unveiled in the UK, as the country desperately searches for alternatives to crippling lockdown measures to prevent the disease from spreading. The breath test has been developed by Integumen in collaboration with Modern Water, Avacta and Aptamer Group, which had been working on test that identifies the SARS-CoV-2 coronavirus in waste water.

Hospitals 133
article thumbnail

Hair Loss – Curbside Consult

Med Ed 101

A 69-year-old female is concerned with hair loss. She states that she does not have a family history of this issue and believes that her medications might be to blame. Her primary provider does not feel as if the hair loss is due to a medical issue (i.e. hypothyroidism etc.). Current diagnoses include: GERD Peptic […]. The post Hair Loss – Curbside Consult appeared first on Med Ed 101.

40
article thumbnail

Role of Pharmacist in Transforming Global Health

Pharma Tutor

About Author Dr. R. S. Thakur. Email: drramsthakur@gmail.com. ABSTRACT. Pharmacists are transforming global health by empowering patients and other health care providers through counselling, drug information and motivation for rational use of medicines. Pharmacists strive to eliminate medication errors and ensure strict patient compliance to achieve desired therapeutic outcomes.

Dosage 56
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

PRA partners on acute leukemia clinical trial

Outsourcing Pharma

The CRO will work with the Leukemia and Lymphoma Society on a global master clinical trial to explore treatments for pediatric acute leukemia.

58
article thumbnail

MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPO

pharmaphorum

Compass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy firm Mind Medicine is aiming to follow suit by up-listing its shares on the Nasdaq. UK-based Compass has a patented synthetic version of psilocybin, the active ingredient in magic mushrooms, and raised around $127.5 million with its IPO on Friday and shares are still significantly above their launch price of $17.

article thumbnail

Omeprazole Escitalopram Interaction – Case Study

Med Ed 101

The omeprazole escitalopram interaction is a relatively common one in clinical practice. Below, I outline a case scenario where this interaction may have caused some adverse effects from escitalopram. An 81-year-old female has a history of depression, GERD, hypertension, and osteoarthritis. Current medications include amlodipine 10 mg daily, hydrochlorothiazide 12.5 mg daily, escitalopram 20 mg […].

40
article thumbnail

Oncimmune partners with Genentech to profile samples from rheumatology trials

Pharma Times

UK-headquartered company will characterise autoantibody profiles of clinical trial patients

49
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Thermo Fisher to collaborate on biomarker discovery project

Outsourcing Pharma

Thermo Fisher Scientific will partner with AstraZeneca and the University of Nebraska Medical Center to advance biomarker discovery and characterization.

52
article thumbnail

Amazon bolsters Alexa’s health credentials with Sharecare deal

pharmaphorum

Amazon’s Alexa device can already field health and medical questions, but the library of responses has now been bulked up thanks to a partnership with digital health company Sharecare. The new deal adds more than 80,000 questions and answers to the repertoire of the Alexa virtual assistant, which provides information, entertainment and advice to users on voice command via devices such as Amazon’s Echo smart speakers.

article thumbnail

Cognoa preps FDA filing for digital autism diagnostic

pharmaphorum

An artificial intelligence-powered diagnostic for autism spectrum disorder (ASD), developed by Cognoa, has met all its objectives in a pivotal trial and will be filed for approval with the FDA. The ASD diagnostic app is designed to serve as a tool that can be used by paediatricians in primary care to detect autism traits early on and start treatment sooner.

FDA 120
article thumbnail

New study reveals patients’ changing needs during COVID-19

pharmaphorum

New research from The Patients Association, supported through sponsorship provided by Novo Nordisk and ENGINE MHP, looks at how more than 950 patients experienced the COVID-19 pandemic, with an emphasis on managing and accessing care and their experiences of treatment and services more broadly. Here, Patients Association CEO Rachel Power and ENGINE MHP director Jonathon Sheppard explore some of the findings – such as major disruptions to the relationships between patients and the health and care

article thumbnail

Life in phase III: How effective data management can support NHS Trusts to hit their targets

pharmaphorum

Although life for the general public is (slowly) starting to edge back towards normality, healthcare providers are still on a heightened state of alert. In the UK, the 1 August step down from EPRR incident level four may have meant we’re no longer in a state of national incident, but at a regional level NHS Trusts and private sector providers are still very much working flat out to manage and contain COVID-19 and its associated fallout.

article thumbnail

UK university strikes e-prescribing partnership with Better

pharmaphorum

A UK university has struck a partnership with medical technology firm Better that aims to give nursing and pharmacy students a better insight into e-prescribing. Liverpool John Moores University is to use Better’s OPENeP electronic prescribing and medicines administration software to teach the students about modern prescribing practices. OPENeP is designed as a stand-alone product that allows electronic patient record systems to be integrated with medication-related decision support systems.

Hospitals 111
article thumbnail

Aerpio starts trial of drug for COVID blood vessel damage

pharmaphorum

One of the less well-known symptoms of COVID-19 is inflammation and injury to blood vessels, and US biotech Aerpio Pharma thinks it has a drug that may help avert the life-threatening blood clots that can result. Ohio-based Aerpio has started a phase 2 trial of its razuprotafib drug, given as a subcutaneous injection three times a day, to hospitalised subjects with moderate to severe COVID-19, to see if it can stabilise blood vessels in their lungs and other organs.

Hospitals 101
article thumbnail

Gilead pays $97m to resolve US illegal kickback claims

pharmaphorum

Gilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a charitable foundation as a conduit to fund co-payments of thousands of Medicare patients taking its pulmonary arterial hypertension drug, Letairis. While this may sound innocuous, the US Department of Justice is cracking down on this activity as it undermines US laws that aim to place a check on drug prices on the federally-funded Medicare scheme.

article thumbnail

Immunomedics wows ESMO with breast cancer data reveal

pharmaphorum

Immunomedics has revealed the trial data that convinced Gilead to stage a $21 billion takeover , after the biotech’s Trodelvy significantly extended survival in patients with tough-to-treat triple negative breast cancer. In April, Trodelvy was conditionally approved in the US in triple-negative breast cancer (TNBC) on the basis of a phase 1/2 study, which showed a response rate of 33%.

article thumbnail

UK government launches COVID-19 app as cases soar

pharmaphorum

The UK government has finally launched its COVID-19 test and trace app months behind schedule as the country faces a second wave of the potentially deadly virus. There have already been hundreds of thousands of downloads of the app, which was seen as a key part of the government’s strategy to fight the virus when it was announced in May. But a pilot scheme of the app in the Isle of Wight hit problems almost immediately because of the government’s decision to use a centralised database, instead o

article thumbnail

Novavax begins late-stage trial of COVID-19 vaccine in the UK

pharmaphorum

Novavax has begun a late-stage trial of its experimental COVID-19 vaccine in the UK, which could support filings for a licence in the UK, EU and other countries. The UK government has already signed an agreement with the US biotech to buy 60 million doses of the vaccine in August if trials work out. It’s one of several agreements with major vaccine makers as the UK hedges its bets over which of the shots will get okayed by regulators first.

article thumbnail

Drama as J&J partner Legend’s CEO is detained after Chinese customs raids

pharmaphorum

Just a month after taking up the CEO role at Legend Biotech, Frank Zhang has been forced to step aside by the board following an investigation into suspected illegal activity by Chinese customs. The nature of the probe isn’t being disclosed at the moment, but according to Legend involves “suspected violations of import and export regulations” at the company’s parent company GenScript Biotech, as well as subsidiaries including Legend.

article thumbnail

New data reinforce Keytruda’s dominance in first-line lung cancer

pharmaphorum

Five-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off a growing number of contenders to the first-line non-small cell lung cancer (NSCLC) market. The follow-up results from the phase 3 KEYNOTE-024 trial showed almost a third (31.9%) of patients whose tumours expressed high levels (50% or greater) of the biomarker PD-L1 who were treated with Keytruda (pembrolizumab) were still alive after five years, compared to 16.3% of the chemo group.

article thumbnail

Online Pharma Forecasting Training for Everyone Now Available

pharmaphorum

Online Pharma Forecasting Training for Individuals or Groups is Now Available. Pharmaceutical forecasting can be challenging particularly during this time. Recognised as the pharmaceutical forecasting experts, J+D Forecasting has created several online pharma forecasting courses. Following the success of J+D Forecasting’s face to face training , the content has been redesigned to make it suitable for an online audience.

75
article thumbnail

Gilead’s rheumatoid arthritis pill approved in Japan

pharmaphorum

Gilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted it a licence following an FDA rejection in August. The California biotech and marketing partner Eisai announced the Japanese Ministry of Health, Labour and Welfare had approved the drug under the brand name Jyseleca. The JAK1 inhibitor class drug offers a once-daily oral option for rheumatoid arthritis patients who have had an inadequate response to conventional therapies,

FDA 72
article thumbnail

AC Immune poleaxed on Alzheimer’s study fail

pharmaphorum

Shares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a phase 2 trial in Alzheimer’s disease (AD). The Swiss biotech’s Nasdaq-listed shares were down almost 44% in pre-market trading today in the wake of the announcement. The TAURIEL study seems to have failed across the board, at least at this preliminary data readout stage.

article thumbnail

FDA fast-tracks Leap’s gastric cancer immunotherapy

pharmaphorum

Leap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric and gastroesophageal junction (G/GEJ) cancer after being awarded fast-track status by the regulator. DKN-01 is an antibody drug targeting the Dickkopf-1 (DKK1) protein, which is overexpressed in some forms of G/GEJ adenocarcinoma and is thought to be involved in tumour growth as well as dampening down the immune response against the cancer.

FDA 62
article thumbnail

Salvia raises 26 million euros to finance migraine neurostimulation therapy

pharmaphorum

Salvia BioElectronics has raised 26 million euros ($30 million) in new financing to fund development of a neurostimulation therapy for chronic migraine. Neurostimulation has been proven as an effective treatment in chronic migraine, but there are no approved implantable devices currently available. Bioelectronics are smart devices using mild electrical impulses to influence nerve activity and is already well established in other fields of medicine – cardiac pacemakers have been in use for decade

59
article thumbnail

Roche bulks up in inflammation with €380m Inflazome acquisition

pharmaphorum

Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Inflazome a couple of years after snapping up Jecure Therapeutics of the US for an undisclosed sum. The Swiss pharma giant is paying €380 million (around $450 million) upfront for Dublin-based Inflazome, getting rights to a portfolio of oral NLRP3-targeting drugs including two candidates at the clinical testing stage, and has also pledged undisclosed milestone payments.

article thumbnail

Amgen offers hope in KRAS-mutated cancer with sotorasib read-out

pharmaphorum

Last year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug that seemed to work against KRAS mutations, which are found in lung and other cancers but have proved hard to treat. At this year’s European Society for Medical Oncology (ESMO) conference, Amgen announced updated data from the full phase 1 cohort of the CodeBreak 100 study.

59